KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma
Authors
Keywords
-
Journal
BRITISH JOURNAL OF DERMATOLOGY
Volume 175, Issue 2, Pages 325-333
Publisher
Wiley
Online
2016-04-03
DOI
10.1111/bjd.14626
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- KIR3DL2/CpG ODN Interaction Mediates Sézary Syndrome Malignant T Cell Apoptosis
- (2015) Bouchra Ghazi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- KIR3DL2 is a coinhibitory receptor on Sezary syndrome malignant T cells that promotes resistance to activation-induced cell death
- (2014) N. Thonnart et al. BLOOD
- IPH4102, a Humanized KIR3DL2 Antibody with Potent Activity against Cutaneous T-cell Lymphoma
- (2014) A. Marie-Cardine et al. CANCER RESEARCH
- Use of PLS3, Twist, CD158k/KIR3DL2, and NKp46 gene expression combination for reliable Sezary syndrome diagnosis
- (2013) L. Michel et al. BLOOD
- Complete Response of Relapsed Systemic and Cutaneous Anaplastic Large Cell Lymphoma Using Brentuximab Vedotin: 2 Case Reports
- (2013) Alessandro Broccoli et al. Clinical Lymphoma Myeloma & Leukemia
- NKp46-Specific Expression on Skin-Resident CD4 + Lymphocytes in Mycosis Fungoides and Sézary Syndrome
- (2013) Pierre Schneider et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma
- (2012) R. A. de Claro et al. CLINICAL CANCER RESEARCH
- CD158k/KIR3DL2 and NKp46 are frequently expressed in transformed mycosis fungoides
- (2012) Nicolas Ortonne et al. EXPERIMENTAL DERMATOLOGY
- EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma
- (2011) W. Kempf et al. BLOOD
- Expression and Function of the Natural Cytotoxicity Receptor NKp46 on Circulating Malignant CD4+ T Lymphocytes of Sézary Syndrome Patients
- (2010) Armand Bensussan et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma
- (2009) Denise K. Woo et al. ARCHIVES OF DERMATOLOGY
- Applicability and Prognostic Value of the New TNM Classification System in 135 Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma
- (2009) Marchina F. Benner et al. ARCHIVES OF DERMATOLOGY
- Absolute CD3+âCD158k+ lymphocyte count is reliable and more sensitive than cytomorphology to evaluate blood tumour burden in Sézary syndrome
- (2009) J.-D. Bouaziz et al. BRITISH JOURNAL OF DERMATOLOGY
- Resistance of Cutaneous Anaplastic Large-Cell Lymphoma Cells to Apoptosis by Death Ligands Is Enhanced by CD30-Mediated Overexpression of c-FLIP
- (2009) Frank K. Braun et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- CD158K/KIR3DL2 Transcript Detection in Lesional Skin of Patients with Erythroderma Is a Tool for the Diagnosis of Sézary Syndrome
- (2007) Nicolas Ortonne et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started